Cansino Biologics Inc (688185) — Capital Reinvestment Ratio
Latest as of September 2025:
1.45x
Cansino Biologics Inc (688185) has a Capital Reinvestment Ratio of 1.45x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥30.53 Million) in capital expenditures (CN¥44.23 Million). See 688185 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.45x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥30.53 Million
CNY
Capital Expenditures
CN¥44.23 Million
CNY
Data as of
Sep 2025
Most recent filing
Cansino Biologics Inc Capital Reinvestment Ratio (2021–2025)
This chart tracks Cansino Biologics Inc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Cansino Biologics Inc (2021–2025)
Year-by-year Capital Reinvestment Ratio for Cansino Biologics Inc from 2021 to 2025. For live market cap and broader valuation context, see Cansino Biologics Inc market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 3.13x | CN¥77.86 Million | CN¥243.90 Million | ▲ +424.5% |
| 2021 | 0.60x | CN¥2.01 Billion | CN¥1.20 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow